Pain intensity of chronic non-cancer patients was reduced by cannabinoids consumption , but effect sizes were small .
Efficacy for neuropathic and non-neuropathic pain was similar
There is growing interest in using cannabinoids for chronic pain .
We performed a systematic review and meta- analysis of r and omized controlled trials to evaluate the analgesic efficacy and adverse effects of cannabinoids for chronic non-cancer pain .
Effects on Spasticity and Neuropathic Pain of an Oral Formulation of Δ9-tetrahydrocannabinol in Patients WithProgressive Multiple Sclerosis.
PURPOSE The aim of the present study was to evaluate the efficacy of an oral formulation of Δ9-tetrahydrocannabinol ( ECP002A ) in patients with progressive multiple sclerosis ( MS ) . METHODS This accelerated proof-of-concept study consisted of 2 phases : a crossover challenge ( dose-finding ) phase and a 4-week , parallel , r and omized , placebo-controlled treatment phase . Twenty-four patients with progressive MS and moderate spasticity were enrolled . During the treatment phase , biomarkers for efficacy and secondary pharmacodynamic effects were measured at baseline and after 2 and 4 weeks of treatment . Serum sample s were collected to determine pharmacokinetic properties and perform population modeling . Safety and tolerability profiles were assessed based on adverse events and safety measurements . FINDINGS Pain was significantly reduced when measured directly after administration of ECP002A in the clinic but not when measured in a daily diary . A similar pattern was observed in subjective muscle spasticity . Other clinical outcomes were not significantly different between active treatment and placebo . Cognitive testing indicated that there was no decline in cognition after 2 or 4 weeks of treatment attributable to ECP002A compared with placebo . Implication s This study specifically underlines the added value of thorough investigation of pharmacokinetic and pharmacodynamic associations in the target population . Despite the complex interplay of psychoactive effects and analgesia , the current oral formulation of Δ9-tetrahydrocannabinol may play a role in the treatment of spasticity and pain associated with MS because it was well tolerated and had a stable pharmacokinetic profile
Pain intensity of chronic non-cancer patients was reduced by cannabinoids consumption , but effect sizes were small .
Efficacy for neuropathic and non-neuropathic pain was similar
There is growing interest in using cannabinoids for chronic pain .
We performed a systematic review and meta- analysis of r and omized controlled trials to evaluate the analgesic efficacy and adverse effects of cannabinoids for chronic non-cancer pain .